Regenicin, Inc.
RGIN · OTC
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $491 | $3,070 | $1,842 | $2,916 |
| - Cash | $15 | $2 | $1 | $1 |
| + Debt | $643 | $603 | $578 | $455 |
| Enterprise Value | $1,119 | $3,671 | $2,419 | $3,370 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$601 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$601 | -$636 | -$511 | -$737 |
| % Margin | – | – | – | – |
| Net Income | -$639 | -$671 | -$560 | -$758 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.005 | -0.005 | -0.004 | -0.005 |
| % Growth | 6.2% | -17.1% | 19.6% | – |
| Operating Cash Flow | -$27 | -$24 | -$123 | -$127 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$27 | -$24 | -$123 | -$127 |